MMED (NASDAQ:MMED) Coverage Initiated at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank initiated coverage on MMED with a Buy rating and a $20 price target, implying roughly a 39% upside from the prior close.
• Multiple firms also started coverage (Morgan Stanley Overweight $19, Wells Fargo Overweight $26, BTIG Buy $25, William Blair Outperform), leaving MMED with a MarketBeat consensus of 10 Buys, 1 Hold and a $22.10 consensus target.
• MMED opened at $14.35 (near its 52‑week low of $14.10 and well below the $20.48 high) and is a scaled global medical‑technology company that commercializes an integrated diabetes management system.

Investment analysts at Deutsche Bank Aktiengesellschaft initiated coverage on shares of MMED (NASDAQ:MMED - Get Free Report) in a research report issued on Tuesday. The brokerage set a "buy" rating and a $20.00 price target on the stock. Deutsche Bank Aktiengesellschaft's price target points to a potential upside of 39.37% from the company's previous close.

A number of other research firms have also weighed in on MMED. Wall Street Zen raised MMED to a "hold" rating in a research report on Saturday, March 14th. Morgan Stanley started coverage on MMED in a research note on Tuesday. They issued an "overweight" rating and a $19.00 target price on the stock. William Blair started coverage on MMED in a report on Tuesday. They set an "outperform" rating for the company. Wells Fargo & Company began coverage on shares of MMED in a research note on Tuesday. They issued an "overweight" rating and a $26.00 price target on the stock. Finally, BTIG Research began coverage on shares of MMED in a research report on Tuesday. They set a "buy" rating and a $25.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $22.10.

MMED Trading Down 0.8%

MMED stock opened at $14.35 on Tuesday. MMED has a 52-week low of $14.10 and a 52-week high of $20.48.

About MMED

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.